| Identification | Back Directory | [Name]
Benzamide, 2,6-difluoro-N-[1-[(2-phenoxyphenyl)methyl]-1H-pyrazol-3-yl]- | [CAS]
1253186-46-7 | [Synonyms]
GSK-5503A
Benzamide, 2,6-difluoro-N-[1-[(2-phenoxyphenyl)methyl]-1H-pyrazol-3-yl]- | [Molecular Formula]
C23H17F2N3O2 | [MOL File]
1253186-46-7.mol | [Molecular Weight]
405.4 |
| Hazard Information | Back Directory | [Description]
GSK-5503A is a novel selective CRAC channel blocker. | [Uses]
GSK-5503A is a calcium-release activated calcium (CRAC) channel blocker. GSK-5503A effectively inhibits stromal interaction molecule 1 (STIM1) mediated Orai1 and Orai3 currents in vitro. GSK-5503A can be used for the research of asthma and allergic disorders[1]. | [References]
[1] Derler I, et al. The action of selective CRAC channel blockers is affected by the Orai pore geometry. Cell Calcium. 2013 Feb;53(2):139-51. DOI:10.1016/j.ceca.2012.11.005 |
|
|